Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli Causing Bloodstream Infections in Three Hospitals in Shanghai, China.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Gene Expression Regulation, Bacterial*; Anti-Bacterial Agents/*pharmacology ; Bacteremia/*epidemiology ; Drug Resistance, Multiple, Bacterial/*genetics ; Escherichia coli/*genetics ; Escherichia coli Infections/*epidemiology; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bacteremia/drug therapy ; Bacteremia/microbiology ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Child ; Child, Preschool ; China/epidemiology ; Disk Diffusion Antimicrobial Tests ; Escherichia coli/classification ; Escherichia coli/drug effects ; Escherichia coli/enzymology ; Escherichia coli Infections/drug therapy ; Escherichia coli Infections/microbiology ; Female ; Humans ; Isoenzymes/genetics ; Isoenzymes/metabolism ; Male ; Middle Aged ; Molecular Epidemiology ; Multilocus Sequence Typing ; Phylogeny ; Polymerase Chain Reaction ; Retrospective Studies ; beta-Lactamases/genetics ; beta-Lactamases/metabolism
    • Abstract:
      Escherichia coli (E. coli) is one of the most frequent and lethal causes of bloodstream infections (BSIs). We carried out a retrospective multicenter study on antimicrobial resistance and phylogenetic background of clinical E. coli isolates recovered from bloodstream in three hospitals in Shanghai. E. coli isolates causing BSIs were consecutively collected between Sept 2013 and Sept 2014. Ninety isolates randomly selected (30 from each hospital) were enrolled in the study. Antimicrobial susceptibility testing was performed by disk diffusion. PCR was used to detect antimicrobial resistance genes coding for β-lactamases (TEM, CTX-M, OXA, etc.), carbapenemases (IMP, VIM, KPC, NDM-1 and OXA-48), and phylogenetic groups. eBURST was applied for analysis of multi-locus sequence typing (MLST). The resistance rates for penicillins, second-generation cephalosporins, fluoroquinolone and tetracyclines were high (>60%). Sixty-one of the 90 (67.8%) strains enrolled produced ESBLs and no carbapenemases were found. Molecular analysis showed that CTX-M-15 (25/61), CTX-M-14 (18/61) and CTX-M-55 (9/61) were the most common ESBLs. Phylogenetic group B2 predominated (43.3%) and exhibited the highest rates of ESBLs production. ST131 (20/90) was the most common sequence type and almost assigned to phylogenetic group B2 (19/20). The following sequence types were ST405 (8/90) and ST69 (5/90). Among 61 ESBL-producers isolates, B2 (26, 42.6%) and ST131 (18, 29.5%) were also the most common phylogenetic group and sequence type. Genetic diversity showed no evidence suggesting a spread of these antimicrobial resistant isolates in the three hospitals. In order to provide more comprehensive and reliable epidemiological information for preventing further dissemination, well-designed and continuous surveillance with more hospitals participating was important.
    • References:
      J Antimicrob Chemother. 2012 Nov;67(11):2612-20. (PMID: 22843833)
      Expert Rev Anti Infect Ther. 2015 May;13(5):575-91. (PMID: 25805210)
      Clin Microbiol Infect. 2013 Jun;19(6):492-500. (PMID: 23398633)
      Clin Microbiol Infect. 2013 Jun;19(6):501-9. (PMID: 23473333)
      Appl Environ Microbiol. 2000 Oct;66(10):4555-8. (PMID: 11010916)
      J Clin Microbiol. 2002 Jun;40(6):2153-62. (PMID: 12037080)
      J Bacteriol. 2004 Mar;186(5):1518-30. (PMID: 14973027)
      J Antimicrob Chemother. 2006 Jan;57(1):154-5. (PMID: 16284100)
      Curr Opin Pharmacol. 2007 Oct;7(5):459-69. (PMID: 17875405)
      J Antimicrob Chemother. 2008 Feb;61(2):273-81. (PMID: 18077311)
      J Antimicrob Chemother. 2009 Apr;63(4):659-67. (PMID: 19233898)
      J Clin Microbiol. 2010 May;48(5):1726-31. (PMID: 20181897)
      J Antimicrob Chemother. 2010 Jul;65(7):1537-9. (PMID: 20466852)
      Appl Environ Microbiol. 2010 Jul;76(13):4337-45. (PMID: 20453128)
      Clin Infect Dis. 2010 Aug 1;51(3):286-94. (PMID: 20572763)
      Euro Surveill. 2011;16(11). pii: 19819. (PMID: 21435327)
      J Antimicrob Chemother. 2011 Sep;66(9):2002-5. (PMID: 21669947)
      Med Res Rev. 2012 Jan;32(1):216-32. (PMID: 20577973)
      J Clin Microbiol. 2012 Feb;50(2):294-9. (PMID: 22162555)
      J Antimicrob Chemother. 2012 Jun;67(6):1514-24. (PMID: 22438437)
      Diagn Microbiol Infect Dis. 2012 Aug;73(4):354-60. (PMID: 22656912)
      BMC Microbiol. 2013;13:144. (PMID: 23800205)
      PLoS One. 2013;8(11):e79640. (PMID: 24265784)
      Int J Environ Res Public Health. 2013 Dec;10(12):6235-54. (PMID: 24287850)
      Rinsho Byori. 2013 Dec;61(12):1116-22. (PMID: 24605545)
      Clin Microbiol Rev. 2014 Jul;27(3):543-74. (PMID: 24982321)
      Future Microbiol. 2015;10(3):407-25. (PMID: 25812463)
      Infect Dis (Lond). 2015 May;47(5):310-8. (PMID: 25712794)
      Epidemiol Infect. 2013 Jan;141(1):174-80. (PMID: 22417845)
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Bacterial Proteins)
      0 (Isoenzymes)
      EC 3.5.2.6 (beta-Lactamases)
      EC 3.5.2.6 (carbapenemase)
    • Publication Date:
      Date Created: 20160130 Date Completed: 20160706 Latest Revision: 20220310
    • Publication Date:
      20240104
    • Accession Number:
      PMC4733056
    • Accession Number:
      10.1371/journal.pone.0147740
    • Accession Number:
      26824702